Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma

Mj, Wang; Zhu, Yibing; Xj, Guo; Zz, Tian

doi:10.4238/2015.september.28.17

Cited by 15 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An association with better event-free survival was reported for the GA/AA genotypes of ERCC2 rs1799793 polymorphism compared to GG genotype [ 69 ] and for patients with at least one polymorphic allele (GA/AA) [ 72 ]. In concordance with this evidence, other two studies showed that the AA genotype correlated with better response to chemotherapy and overall survival compared with the GG genotype [ 66 , 73 ].…”

Section: Pharmacogenetic and Pharmacogenomic Markers Associated Wisupporting

confidence: 72%

“…The CC genotype of the ERCC1 rs11615 polymorphism was found to be associated with good response to cisplatin-based chemotherapy and better overall survival when compared to TT genotype [ 60 , 61 , 62 , 63 , 64 ]. However, other studies described the opposite evidence, being a better survival associated with the TT compared to CC genotype [ 65 , 66 ].…”

Section: Pharmacogenetic and Pharmacogenomic Markers Associated Wimentioning

confidence: 99%

See 1 more Smart Citation

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Hattinger

Patrizio

Luppi

et al. 2020

IJMS

View full text Add to dashboard Cite

High-grade osteosarcoma (HGOS) is a very aggressive bone tumor which primarily affects adolescents and young adults. Although not advanced as is the case for other cancers, pharmacogenetic and pharmacogenomic studies applied to HGOS have been providing hope for an improved understanding of the biology and the identification of genetic biomarkers, which may impact on clinical care management. Recent developments of pharmacogenetics and pharmacogenomics in HGOS are expected to: i) highlight genetic events that trigger oncogenesis or which may act as drivers of disease; ii) validate research models that best predict clinical behavior; and iii) indicate genetic biomarkers associated with clinical outcome (in terms of treatment response, survival probability and susceptibility to chemotherapy-related toxicities). The generated body of information may be translated to clinical settings, in order to improve both effectiveness and safety of conventional chemotherapy trials as well as to indicate new tailored treatment strategies. Here, we review and summarize the current scientific evidence for each of the aforementioned issues in view of possible clinical applications.

show abstract

Section: Pharmacogenetic and Pharmacogenomic Markers Associated Wisupporting

confidence: 72%

Section: Pharmacogenetic and Pharmacogenomic Markers Associated Wimentioning

confidence: 99%

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Hattinger

Patrizio

Luppi

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Previous studies have examined the association between ERCC5rs2094258 and rs751402 polymorphisms and the development of certain malignancies, including breast and gastric cancers, salivary gland tumors, and oral squamous cell carcinoma (Duan et al, 2012;Yang et al, 2012;Zavras et al, 2012;Meng et al, 2013;Na et al, 2015;Wang et al, 2015). For instance, Duan et al (2012) and Yang et al (2012) both reported that these polymorphisms contribute to the development of gastric cancer.…”

Section: Discussionmentioning

confidence: 99%

“…In another case-control investigation, Na et al (2015) assessed 324 breast cancer patients and 325 controls, and revealed that the ERCC5rs2094258 polymorphism may contribute to the development of this disease. However, in a Chinese study, Wang et al (2015) reported that ERCC5 genetic polymorphisms do not affect outcome of treatment for osteosarcoma. Thus, previous studies tend to suggest that ERCC5rs2094258 and rs751402 polymorphisms contribute to cancer risk.…”

Section: Discussionmentioning

confidence: 99%

Lack of association between ERCC5 gene polymorphisms and gastric cancer risk in a Chinese population

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We conducted a case-control study to assess the association between single nucleotide polymorphisms in the ERCC5 promoter (rs2094258 and rs751402) and development of gastric cancer in a Chinese population. This investigation included 184 patients with pathologically diagnosed gastric cancer and 206 healthy subjects recruited between October 2012 and December 2014. The genotyping of ERCC5 rs2094258 and rs751402 variants was performed by polymerase chain reaction coupled with restriction fragment length polymorphism. Genotype distributions of these polymorphisms conformed to HardyWeinberg equilibrium in both patient (P = 0.25 for rs2094258 and P = 0.61 for rs751402) and control groups (P = 0.48 for rs2094258 and P = 0.42 for rs751402). Using unconditional logistic regression analysis, we found that neither of these ERCC5 variants was associated with increased risk of gastric cancer under co-dominant, dominant, or recessive models (P < 0.05). In conclusion, we suggest that the rs2094258 and rs751402 polymorphisms are not connected to the development of this disease under codominant, dominant, and recessive models.

show abstract

“…[10] While there are also results suggested that the ERCC1 rs11615 TT genotype and ERCC2 rs1799793 AA genotype were associated with longer overall survival when compared with those with the wild-type genotype. [11] The conclusions on ERCC2 polymorphism were also inconsistent. Some studies suggested no association between ERCC2 rs13181 polymorphisms and overall survival in patients with osteosarcoma under cisplatin-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy

Liu¹,

Liu

2018

Medicine

View full text Add to dashboard Cite

Aim:To make an accurate estimation of the association of ERCC1 and ERCC2 polymorphisms with osteosarcoma (OS) prognosis in Chinese population.Methods:Total 7 qualified studies with 1404 osteosarcoma patients were included. Odds ratios (OR) with 95% CIs were pooled for the survival rate in different osteosarcoma patients with ERCC1 and ERCC2 genetic polymorphisms. The heterogeneity was assessed by I2 test. Potential publication bias was assessed by Begg funnel plot and Egger linear regression test.Results:In rs11615, no significant association was found under dominant [TT+TC vs. CC: OR = 1.252, 95% CI:0.864–1.815, P = .235], recessive [TT vs. TC+CC: OR = 0.850, 95% CI: 0.695–1.030, P = .095] or allelic model [T vs. C Allele: OR = 1.219, 95% CI: 0.922–1.612, P = .165]. In rs13181, no significant association was found under dominant [AA+AC vs. CC: OR = 1.031, 95% CI: 0.800–1.329, P = .801], recessive [AA vs. AC+CC: OR = 1.005, 95% CI: 0.875, 1.154, P = .944] or allelic model [A vs. C Allele: OR = 1.009, 95% CI: 0.903–1.128, P = .870]. In rs1799793, no significant association was found under dominant [GG+GA vs. AA: OR = 1.134, 95% CI: 0.884–1.454, P = .322, recessive [GG vs. AG+AA: OR = 1.025, 95% CI: 0.881–1.192, P = .750], or allelic model [G vs. A Allele: OR = 1.046, 95% CI: 0.930–1.177, P = .450].Conclusion:This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.

show abstract

Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma

Cited by 15 publications

References 14 publications

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Lack of association between ERCC5 gene polymorphisms and gastric cancer risk in a Chinese population

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy

Contact Info

Product

Resources

About